Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
Giorgio Bogani, Robert L. Coleman, Ignace Vergote, Toon Van Gorp, Isabelle Ray‐Coquard, Ana Oaknin, Ursula A. Matulonis, David M. O’Malley, Francesco Raspagliesi, Giovanni Scambia, Bradley J. Monk
Topics & Concepts
MedicineOvarian cancerInternal medicineOncologyClinical trialFolate receptorAntibodyAdjuvantPopulationPhases of clinical researchCancerGynecologyImmunologyCancer cellEnvironmental healthOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyToxin Mechanisms and Immunotoxins